Clinical study of jianpiyishen granules and Western medicine in the treatment of fragile DLBCL in the elderly

Guang'anmen Hospital0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1. Patients with CD20-positive initial treatment of large B-cell lymphoma with pathological diagnosis;
•2. Age = 60 years old, male or female;
•3. Ann Arbor/Cotswords Phase I-IV;
•4. CGA assessment of patients before treatment, and elderly vulnerable patients who are not suitable for standardized therapy must meet one of the following criteria: 1) ADL < 5 points; 2) IADL < 6 points; 3) 1 grade 3 to 4 comorbidities (or 8 grade 2 comorbidities> in the MCIRS-G score; 4) Patients with an age = 80 years old need to meet: ADL =5, or IADL =7, or 0-1 in the MCIRS-G score of grade 3 to 4 (or > 5 grade 2 complications);
•5. The expected survival period is more than 6 months;
•6. Alanine aminotransferase (AST)= 2.5×ULN, alanine aminotransferase (ALT)=2.5×ULN, serum creatinine Cr=1.5×ULN;
•7. Volunteer to participate in this study and sign an informed consent form.

•1. Those who have a previous history of blood or non-hematologic tumors undergoing chemoradiotherapy;
•2. In the past 5 years, there is a history of malignant tumors other than skin squamous cell carcinoma, skin basal cell carcinoma, and cervical carcinoma in situ;
•3. Patients with central nervous system involvement;
•4. There is a serious infection that is not controlled;
•5. Have other uncontrolled diseases and the researcher believes that it is not suitable for joiners;
•6. Participating in other clinical studies;
•7. Persons infected with COVID-19(excluding cured patients);
•8. Patients with poor adherence.

发起方

Guang'anmen Hospital